Identification of small molecule agonists of the motilin receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6423-6428

  Heightman, Tom D ^a   Conway, Elizabeth ^a   Corbett, David F ^a   Macdonald, Gregor J ^a   Stemp, Geoffrey ^a   Westaway, Susan M ^a   Celestini, Paolo ^b   Gagliardi, Stefania ^b   Riccaboni, Mauro ^b   Ronzoni, Silvano ^b   Vaidya, Kalindi ^a   Butler, Sharon ^a   McKay, Fiona ^a   Muir, Alison ^a   Powney, Ben ^a   Winborn, Kim ^a   Wise, Alan ^a   Jarvie, Emma M ^a   Sanger, Gareth J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NiKem Research   (Italy)

Author keywords

Agonist; GPCR; Motilin; Receptor

Indexed keywords

BIPHENYL DERIVATIVE; ERYTHROMYCIN; GASTROINTESTINAL AGENT; MEMBRANE RECEPTOR; MOTILIN; MOTILIN RECEPTOR; MOTILIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; MOLECULAR WEIGHT; NONHUMAN; STOMACH ANTRUM; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CELL MEMBRANE; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56249141791     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.071     Document Type: Article

References (22)

1. Christofides N.D., Modlin I.M., Fitzpatrick M.L., and Bloom S.R. Gastroenterology 765 (1979) 903
2. Peeters T.L. Old Herborn University Seminar Monograph 9 (1997) 77
3. Dhir R., and Richter J.E. J. Clin. Gastroenterol. 383 (2004) 237
4. Carreras C.W., Siani M.A., Santi D.V., and Dillon S.B. Analyt. Biochem. 3002 (2002) 146
5. Sann H. Functional Disorders of the Gastrointestinal Tract (2005), IOS Press, G. Krause
6. Verhagen M.A.M.T., Samson M., Maes B., Geypens B.J., Ghoos Y.F., and Smout A.J.P.M. Aliment Pharmacol. Ther. 11 (1997) 1077
7. Koga H., Takanashi H., Itoh Z., and Omura S. Drugs Fut. 273 (2002) 255
8. Russo A., Stevens J.E., Giles N., Krause G., O'Donovan D.G., Horowitz M., and Jones K.L. Aliment Pharmacol. Ther. 203 (2004) 333
9. Talley N.J., Verlinden M., Snape W., Beker J.A., Ducrotte P., Dettmer A., Brinkhoff H., Eaker E., Ohning G., Miner P.B., Mathias J.R., Fumagalli I., Staessen D., and Mack R.J. Aliment Pharmacol. Ther. 1412 (2000) 1653
10. Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., and Mack R.J. Gut 49 (2001) 395
11. Peeters T.L. Neurogastroenterol. Motil. 18 (2006) 1
12. Poitras P., and Peeters T.L. Curr. Opin. Endocrinol. Diabetes Obes. 15 (2008) 54
13. Sanger G.J., and Alpers D.H. Neurogastroenterol. Motil. 30 (2008) 177
14. Mccallum, R. W.; Cynshi, O. Aliment Pharmacol. Ther. 2007, 26(1), 107; See company websites: www.roche.com and www.pfizer.com.
15. Li J.J., Chao H.-G., Wang H., Tino J.A., Lawrence R.M., Ewing W.R., Ma Z., Yan M., Slusarchyk D., Seethala R., Sun H., Li D., Burford N.T., Stoffel R.H., Salyan M.E., Li C.Y., Witkus M., Zhao N., Rich A., and Gordon D.A. J. Med. Chem. 477 (2004) 1704
16. 2) was added. 10 μl from the compound plates was then added immediately to cell plates using a FLIPR 3 calcium imaging instrument and changes in fluorescence were measured over a 1 min timeframe. Maximum change in fluorescence over baseline was used to determine agonist response and concentration-response curves were constructed, using a 4-parameter logistic equation. The intrinsic activity of target compounds was calculated by using the maximum asymptote of its concentration-response curve relative to the maximum asymptote of the motilin concentration-response curve.
17. Corbett D.F., Heightman T.D., Moss S.F., Bromidge S.M., Coggon S.A., Longley M.J., Roa A.M., Williams J.A., and Thomas D.R. Bioorg. Med. Chem. Lett. 1518 (2005) 4014
18. It is unlikely that the activity observed for Compound 22 in the rabbit gastric antrum assay is partly or wholly due to action on the ghrelin receptor: other analogues in the series with no activity at the ghrelin receptor showed comparable or greater activity in the antrum assay (unpublished data); and ghrelin itself does not show enhancement of EFS mediated contractions in rabbit gastric antrum, see. Dass N.B., Hill J., Muir A., Testa T., Wise A., and Sanger G.J. Brit. J. Pharmacol. 140 (2003) 948
19. Depoortere I., Thijs T., Theelemans L., Robberecht P., and Peters T.L. J. Pharmacol. Exp. Ther. 305 (2003) 660
20. Jarvie E.M., North Laidler V.J., Corcoran S., Bassil A., and Sanger G.J. Brit. J. Pharmacol. 150 (2007) 455
21. +).
22. Westaway, S. M.; Brown, S. L.; Conway, E.; Heightman, T. D.; Johnson, C. N.; Lapsley, K.; Macdonald, G. J.; MacPherson, D. T.; Mitchell, D. J.; Myatt, J. W.; Seal, J. T.; Stanway, S. J.; Stemp, G.; Thompson, M.; Colombo, A.; Consonni, A.; Gagliardi, S.; Roccaboni, M.; Ronzoni, S.; Briggs, M. A.; Matthews, K. L.; Stevens, A. J.; Bolton, V. J.; Jarvie, E. M.; Stratton, S. C.; Sanger, G. J. Bioorg. Med. Chem. Lett. 2008, doi:10.1016/j.bmcl.2008.10.072.